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Abstract
Background: Patients with diabetes and chronic kidney disease (CKD) are a complex subset of the growing
number of patients with diabetes, due to multi-morbidity. Gaps between recommended and received care for
diabetes and chronic kidney disease (CKD) are evident despite promulgation of guidelines. Here, we document
gaps in tertiary health-care, and the commonest patient-reported barriers to health-care, before exploring the
association between these gaps and barriers.
Methods: This cross-sectional study recruited patients with diabetes and CKD (eGFR < 60 mL/min/1.73 m2) across 4
large hospitals. For each patient, questionnaires were completed examining clinical data, recommended care, and
patient-reported barriers limiting health-care. Descriptive statistics, subgroup analyses by CKD stage and hospital,
and analyses examining the relationship between health-care gaps and barriers were performed.
Results: 308 patients, of mean age 66.9 (SD 11.0) years, and mostly male (69.5%) and having type 2 diabetes (88.0%),
participated. 49.1% had stage 3, 24.7% stage 4 and 26.3% stage 5 CKD. Gaps between recommended versus received
care were evident: 31.9% of patients had an HbA1c≥ 8%, and 39.3% had a measured blood pressure≥ 140/90 mmHg.
The commonest barriers were poor continuity of care (49.3%), inadequate understanding/education about CKD (43.5%)
, and feeling unwell (42.6%). However, barriers associated with a failure to receive items of recommended care were
inadequate support from family and friends, conflicting advice from and poor communication amongst specialists, the
effect of co-morbidities on self-management and feeling unmotivated (all p < 0.05).
Conclusions: Barriers to health-care varied across CKD stages and hospitals. Barriers associated with a deviation from
recommended care were different for different items of care, suggesting that specific interventions targeting each item
of care are required.
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Background
Diabetes is increasing in incidence and prevalence glo-
bally, with 8.3% of adults estimated to be affected [1].
Diabetes commonly co-exists with chronic kidney dis-
ease and accounts for up to 50% of people who develop
end-stage kidney disease (ESKD) [2].
Together, co-morbid diabetes and CKD is an exemplar
of the global health challenge from multi-morbidity, de-
fined as the coexistence of 2 or more chronic conditions
where 1 is not necessarily more central than the other
[3]. Multi-morbidity is increasing as the population ages
and the rate of non-communicable diseases increases [4]
and is associated with poorer quality of life, and higher
mortality rates [3]. The challenges of multi-morbidity
are not well addressed by contemporary health care
systems or clinical research, which have been framed
around single chronic diseases [3, 4].
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The co-existence of diabetes and CKD has an additive
effect to increase the risk of cardiovascular disease [5],
with a substantial increase in risk of premature mortality
as renal function deteriorates towards end-stage kidney
disease [2]. Health-care costs are also significant with
the estimated unadjusted total expenditure for people
with co-morbid diabetes and CKD in the USA being
more than US $43 billion even in 2011 [6].
Despite the recent publication of guidelines and con-
sensus statements for the management of co-morbid
diabetes and CKD [7–10], there is emerging evidence
that the care of patients with these co-morbidities is
suboptimal. Studies report a gap between recommended
care, as suggested by guidelines, versus received care − a
significant proportion of patients fail to meet treatment
targets, and other recommended health indicators of
quality clinical care such as treatment of cardiovascular
risk factors or anaemia [11–14]. Additionally, there is a
paucity of knowledge surrounding the underpinnings of
this gap and the relative importance of clinical and
health system barriers to health-care, specifically for pa-
tients with co-morbid diabetes and CKD. This is a ne-
cessary step towards improving medical care and finding
an effective and efficient health-care delivery system for
this high risk population [7].
The objectives of this study were to 1) identify the de-
gree to which patients with co-morbid diabetes and
CKD experience recommended health-care as per inter-
nationally endorsed guidelines in the setting of tertiary
health-care 2) quantitatively establish the most signifi-
cant barriers to health-care, from the perspective of pa-
tients in the setting of tertiary health-care and 3)
examine the association between failure to receive guide-
line recommended health-care (care gaps) and the
patient-reported barriers to health-care.
Methods
Study design and setting
This Australian multi-centre study was a research collab-
oration between tertiary hospitals, research institutes, na-
tional consumer stakeholder groups (Diabetes Australia
and Kidney Health Australia) and primary care groups.
The study was conducted across ambulatory diabetes and
renal clinics (serviced or supervised by diabetes and kid-
ney specialists) of 4 large tertiary hospitals in Australia’s 2
most populous cities (Alfred and Monash Health in
Melbourne and the Royal North Shore and Concord Hos-
pitals in Sydney) from January to September 2014. These
specialist ambulatory services communicate with primary
care via written correspondence or phone calls but with-
out any further integration of health-care such as shared
medical records or care plans. Additionally, the ambula-
tory services of 2 of the hospitals (2 and 4), were struc-
tured such that the patient saw the same clinician each
visit. Methods and results are presented in accordance
with the STROBE (Strengthening The Reporting of Ob-
servational Studies in Epidemiology) guidelines [15]. The
study was approved by the Monash University Human Re-
search Ethics Committee (HREC) and the HREC of all
participating sites.
Participants
Patients with both diabetes and CKD were recruited
from either ambulatory diabetes or renal clinics of each
participating tertiary hospital over a 3-month period be-
tween January to September 2014. Patients were defined
as having diabetes if the diagnosis was noted on medical
records and/or confirmed by laboratory results as per
World Health Organisation (WHO) criteria [16]. Pa-
tients were defined as having CKD if they had a sus-
tained estimated glomerular filtration rate (eGFR) <
60 mL/min/1.73 m2 calculated using the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration)
equation [17] (i.e. 2 or more eGFR readings) over a
3 month period. Pregnancy was an exclusion criteria. All
participants gave written informed consent.
Study conduct and variables
Each recruited subject participated in a survey consisting
of two questionnaires. The first questionnaire was pro-
spectively completed by the patient’s doctor during the
clinic or from the doctor’s notes and laboratory results
from clinic and collected demographic information (age,
country of birth, language spoken at home) and other
clinical characteristics (Additional file 1: Appendix: Part
A). The second questionnaire was completed by the pa-
tient and examined patient-reported barriers to health-
care (Additional file 1: Appendix: Part B) identified from
the content analysis of 12 focus groups of 58 partici-
pants with co-morbid diabetes and CKD and 8 semi-
structured interviews of carers from a previous multi-
centre qualitative study performed by the authors [18]
(Additional file 1: Appendix: Part A).
Treatment targets for recommended care
The received care of participants was compared with
treatment targets for recommended care from inter-
national guidelines [7–9, 19, 20]. The authors acknow-
ledge the importance of individual application of
recommended guideline care. For the purposes of this
study, where more than one treatment target was offered
for a particular parameter by different guidelines, the
more conservative and simpler target was used. For ex-
ample for HbA1c, the American Diabetes Association sug-
gestion of HbA1c < 8% (64 mmol/mol) [7] was used rather
than that from the European Renal Best Practice guide-
lines which varied from 7% (53 mmol/mol) to 9%
(75 mmol/mol), depending on the patient’s clinical
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situation [8], or the KDOQI (Kidney Disease Outcomes
Quality Initiative) guidelines which suggest a HbA1c of
~7% (53 mmol/mol) [9].
Statistical analysis
Continuous variables were reported as means and stand-
ard deviations or medians with interquartile ranges if
distributions were skewed. Categorical variables (includ-
ing barriers), cardiovascular risk factors (e.g. hyperchol-
esterolemia, hypertension, smoking etc.) and adherence
to best practice guidelines were reported as frequencies
and percentages. Likert scales were collapsed into 2 cat-
egories (disagree and agree) for questions related to bar-
riers. Clinical characteristics were reported for the entire
cohort and also according to KDOQI CKD stages. Char-
acteristics between KDOQI CKD stages were compared
using Chi square and Fisher Exact tests for categorical
variables. For continuous variables, Student’s t tests for
normally distributed and Kruskal-Wallis tests for skewed
outcomes were used. Adjustments were made for clus-
tering by hospital where possible.
Patient-reported barriers to health-care were ranked
quantitatively according to percentages. Subgroup analyses
for patients occurred according to KDOQI CKD stages (3,
4 and 5ND and 5D) [21] as it was felt that the health expe-
riences of patients with KDIGO (Kidney Disease Improving
Global Outcomes) CKD stage 3a and 3b would be similar.
Chi square and Fisher Exact tests were used to compare be-
tween KDOQI CKD stages for recommended versus re-
ceived care, adjusted for clustering by hospital. A linear
trend analysis was also performed. An additional sub-
analysis of patient-reported barriers to health-care was
done by individual hospital using Chi square and Fisher
Exact tests, with a Bonferroni correction.
The association between gaps in care (compared to
recommended guideline care) and the patient-reported
barriers to health-care were examined by comparing the
percentage of patients who reported a barrier among
those who received recommended care compared to
those who did not, using Chi Square and Fisher Exact
Tests, adjusted for clustering.
To evaluate the likelihood of a responder bias, the fol-
lowing variables were compared between responders and
non-responders at one tertiary health service – age, gen-
der, and KDOQI stages using the Student’s t test and
Chi square statistic. A p value < 0.05 was considered sig-
nificant except for when the Bonferroni correction was
used when a p < 0.0125 was considered significant. All
statistical analyses were performed using STATA v12.1.
Results
Participant characteristics
A total of 821 patients were invited to participate
(see Fig. 1: Patient recruitment) with 316 patients
completing surveys (response rate of 38.5%). Eight patients
were excluded because their eGFR was ≥ 60 mL/min/
1.73 m2 leaving 308 for the analysis. Patients (at one tertiary
health service) who participated in the study were similar
in age, gender distribution and KDOQI CKD stage to those
who did not (Additional file 1: Appendix: Table S1).
Clinical characteristics, cardiovascular risk factors and
biochemical parameters are reported in Table 1. The
mean (SD) age of patients was 66.9 (11.0) years, 69.5%
were male. The cohort was multi-cultural with less than
half born in Australia (46.4%) and only 78% speaking
English as the main language at home. The patients were
generally overweight (mean body mass index or BMI
30.7; SD 7.4) and 94.5% had a history of hypertension.
The majority of patients had type 2 diabetes (88.0%) of
long duration (median 17, IQR 10–23.5 years). Patients
were evenly distributed between KDIGO stages. Close to
one-fifth of patients (19.2%) were receiving dialysis. The
cohort had high cardiovascular risk with 47.0% having a
history of ischemic heart disease. As expected and con-
sistent with the pathophysiology and prognosis of later
stage CKD, patients with earlier CKD stages tended to
Fig. 1 Patient recruitment
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be slightly older, have a higher BMI, have a higher
haemoglobin and HbA1c, have a lower phosphate and
PTH, and have a lesser need for treatment for CKD
metabolic bone disease, compared to later CKD Stages
(Additional file 1: Appendix: Table S2: Characteristics
and medication usage of patients with diabetes and CKD
stratified by CKD stage).
Recommended versus received care for co-morbid dia-
betes and CKD
Documented treatment targets and received care of pa-
tients as compared to recommended treatment targets
and care according to guidelines and consensus state-
ments [7, 8] are shown in Table 2. 31.9% of patients had
an HbA1c ≥ 8% (64 mmol/mol), 39.3% of patients had a
measured systolic blood pressure ≥ 140 mmHg or a dia-
stolic blood pressure ≥ 90 mmHg, and 17.7% of those pa-
tients not on dialysis were not taking a statin. There
were also screening gaps with 12.2% of patients with
documented diabetic retinopathy not having an eye re-
view over the preceding year; and 50.9% of patients with
peripheral neuropathy not having their feet examined at
their 3 monthly review.
On analysis by CKD stage i.e. CKD 3, 4, 5ND and 5D,
although there were numerical differences between
stages, there were no statistical differences in the pro-
portion of patients who did not achieve recommended
treatment targets including an HbA1c ≥ 8%, systolic BP
levels ≥140 and/or diastolic BP levels ≥90 mmHg, not
being on a statin for those with non-dialysis dependent
CKD, not having an eye review over the past year despite
the presence of diabetic retinopathy or not having a foot
examination despite the presence of peripheral neur-
opathy (all p > 0.05, see Fig. 2).
Barriers to health-care for co-morbid diabetes and CKD
The commonest barriers to health-care reported by pa-
tients (Fig. 3 and Additional file 1: Appendix: Table S3)
included poor continuity of care (seeing a different spe-
cialist each visit (49.3%)), inadequate understanding and
education about CKD (43.5%), feeling unwell (42.6%),
and having trouble maintaining dietary and fluid restric-
tions (40.1%). Other barriers according to CKD stage are
shown in the Additional file 1: Appendix: Figure S1:
Other barriers to health-care identified by patients.
The significance of each barrier ranked differently
across the CKD stages (Fig. 3). Poor continuity of care
was the most reported barrier in CKD 5ND (68.2%) and
CKD 3 (50.0%) but was the third most reported barrier
in CKD 5D (43.9%) and the fourth most reported barrier
in CKD 4 (46.7%). Inadequate understanding and educa-
tion about kidney disease was the second most reported
barrier in CKD 3 (49.3%) and CKD 4 (48.0%) and the
fourth most reported barrier in CKD 5ND (40.9%).
Feeling unwell was the most reported barrier in CKD 4
(50.7%) and CKD 5D (51.8%) but was the second most
reported barrier in CKD 5ND (54.6%) and the fourth
most reported barrier in CKD 3 (33.1%). Trouble main-
taining dietary and fluid restrictions was the third most
reported barrier in CKD 3 (37.4%) and 5ND (42.9%) and
the fourth most reported barrier in CKD 5D (38.6%). Fi-
nally, trouble adjusting to the personal, family and social
impact of diabetes and CKD was the second most re-
ported barrier in CKD 5D (47.4%) and the third most re-
ported barrier in CKD 4 (47.3%).
The proportion of patients reporting a particular
barrier as a problem also differed across hospitals
(Additional file 1: Appendix: Table S3: Barriers to
health-care identified by patients per hospital). Across the
hospitals, the reported barriers which differed included
poor continuity of care due to seeing a different specialist,
poor communication from specialists to primary care phy-
sicians, poor communication between specialists, the spe-
cialist providing inadequate information about the disease
and poor relationship with specialist health service staff
(Bonferroni p < 0.0125). The most reported barrier in hos-
pitals 1 and 3 was poor continuity of care due to seeing a
different specialist while the most reported barrier in hos-
pitals 2 and 4 was trouble adjusting to the impact diabetes
and CKD has on his/her life and/or that of his/her family
and friends (Additional file 1: Appendix: Table S4: The
four most common barriers to health-care identified by
patients according to hospital).
Association between recommended care and patient-
reported barriers to health-care
There was an association between the following treatment
recommendations − an HbA1c of < 8% (64 mmol/mol), re-
ceiving an annual eye check in the presence of diabetic ret-
inopathy, and a haemoglobin of 100 – 115 g/L whilst on an
ESA − and patient-reported barriers to health-care. Patients
who did not have a HbA1c of < 8% (64 mmol/mol) more
often reported conflicting advice as an issue (22.4% vs
12.6%, p = 0.04), inadequate support from family (15.9% vs
3.2%, p < 0.01) and inadequate support from friends (18.2%
vs 8.0%, p = 0.02) than those who did have a HbA1c of < 8%
(64 mmol/mol). Patients who did not receive an annual eye
check more often reported poor communication between
specialists (57.1% vs 13.3%, p = 0.01) and comorbidities af-
fecting the ability to self-manage (66.7% vs 18.9% p = 0.02)
than those who did receive an annual eye check. Finally, pa-
tients on an ESA who did not have a haemoglobin of 100 –
115 g/L more often reported feeling unmotivated to self-
manage (29.6% vs 5.3%, p = 0.047) than those that did have
a haemoglobin of 100 – 115 g/L.
There was no association between the following treat-
ment recommendations − blood pressure < 140/90 mmHg,
receiving treatment with a statin if aged > 40 with non-
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dialysis dependent CKD, having feet examined in the set-
ting of a diagnosis of peripheral neuropathy, and appropri-
ate metformin and ESA prescription − and patient-reported
barriers to health-care.
Discussion
This multi-centre study informs improvement of current
models of care for those with co-morbid diabetes and
CKD by documenting the presence of gaps between rec-
ommended and received care in the tertiary health-care
setting and quantitatively identifying the barriers to
health-care reported by patients. These barriers varied
between hospital and CKD stage, with the most reported
barriers being poor continuity of care due to seeing a
different specialist, inadequate understanding and educa-
tion about CKD, feeling unwell and trouble maintaining
dietary and fluid restrictions, with some variation ac-
cording to CKD stage and hospital. Interestingly, these
were not associated with recommended care. The only
reported barriers associated with a failure to receive rec-
ommended care were conflicting advice from specialists
and inadequate support from family and friends being
associated with a HbA1c ≥ 8% (64 mmol/mol), poor
communication between specialists and the effect of co-
morbidities on self-management being associated with
not receiving an annual eye check in the presence of dia-
betic retinopathy, and feeling unmotivated to self-
manage being associated with a failure to reach a
haemoglobin target of 100 – 115 g/L whilst on an ESA.
Table 1 Characteristics and Medication usage of patients with
diabetes and CKD
Clinical Characteristic Total (n = 308)
Age (SD) 66.9 (11.0)
Male/Female (%) 214 (69.5)/94 (30.5)
Main language spoken at home
(% English)
238/305 (78.0)
Australia as the country of birth 141/304 (46.4)
Body weight (IQR) kg 86.1 (72.8 – 101.3)
Height (SD) m 1.68 (0.10)
BMI (SD) kg/m2 30.7 (7.4)
Systolic blood pressure (SD) mmHg 134 (18)
Diastolic blood pressure (SD) mmHg 72 (11)
Active Smoker (%) 18/230 (7.8)
Diabetes duration (IQR) yrs. 17.0 (10.0 – 23.5)
Diabetes type (%)
type 1 28 (9.1)






5 (inclusive of 5D) 81 (26.3)
Dialysis (%) 59 (19.2)
Haemodialysis (%) 42 (71.1)
Peritoneal dialysis (%) 17 (28.9)
Other multi-morbidity
Hypertension (%) 291/308 (94.5)
Dyslipidaemia (%) 256/308 (83.1)
Ischemic Heart Disease (%) 143/304 (47.0)
Stroke (%) 38/305 (12.5)
Peripheral Vascular Disease (%) 82/304 (27.0)
Diabetic Retinopathy (%) 132/305 (43.3)
Diabetic Neuropathy (%) 108/305 (35.4)




Haemoglobin (SD) g/L 122 (18)
HbA1c % 7.3 (6.4 – 8.3)
HbA1c (mmol/mol) 56 (47 – 67)
Total Cholesterol (IQR) mmol/L 3.9 (3.4 – 4.6)
LDL (IQR) mmol/L 1.8 (1.4 – 2.5)
HDL (IQR) mmol/L 1 (0.8 – 1.2)
Triglycerides (IQR) mmol/L 1.8 (1.2 – 2.5)
Potassium (SD) mmol/L 4.6 (0.6)
Calcium (SD) mmol/L 2.31 (0.14)
Table 1 Characteristics and Medication usage of patients with
diabetes and CKD (Continued)
Phosphate (IQR) mmol/L 1.23 (1.08 – 1.46)
PTH (IQR) pmol/L 15.7 (7.8 – 30.6)
Medication Usage




Both insulin and non-insulin
glucose lowering therapy (%)
67 (21.8)
Diet only with other glucose
lowering therapies (%)
20 (6.5)
Statin use (%) 248 (80.5)
Fibrate (%) 34 (11.0)
Use of any antihypertensive (%) 278 (90.3)
Use of ACEI and/or AT2RB (%) 185 (60.1)
Use of other antihypertensive
besides an ACEI/AT2RB (%)
240 (77.9)
ESA use (%) 64 (20.8)
Iron supplementation (%) 57 (18.5)
Phosphate binder (%) 58 (18.8)
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Our Australian data add to the growing international
data demonstrating the presence of guideline-care gaps
amongst patients with diabetes and CKD. Despite the
lack of information for whom targets may have been
individualised (for safety/tolerability reasons), our results
suggest significant care gaps with more than 30% of pa-
tients having an HbA1c ≥ 8% (64 mmol/mol) and close
to 40% of patients having a blood pressure ≥ 140/
90 mmHg. The magnitude of these gaps is comparable
to other cross-sectional surveys of patients with diabetes
and CKD [11, 12]. They are of particular concern given
the increased morbidity, mortality and health care costs
associated with these conditions. This emphasises the
need for strategies to address these gaps in order to
build on areas where care is better, such as prescription
of statins in non-dialysis patients or annual eye reviews.
The four most reported barriers to health-care were
poor continuity of care due to seeing a different specialist,
inadequate understanding and education about CKD, feel-
ing unwell and trouble maintaining dietary and fluid re-
strictions, with some variation according to CKD stage
and hospital. Poor continuity of care was mainly reported
in hospitals where patients attended clinics with multiple
specialists (hospitals 1 and 3), rather than patients attend-
ing a clinic where they saw the same clinician. Previous
studies amongst patients with CKD alone, have reported
that self-awareness of the diagnosis of CKD 3 and 4 was
poor [22], and knowledge about CKD and its complica-
tions was low [23]. Similarly, patients with CKD have been
described to have a high symptom burden, with fatigue,
drowsiness, pain and decreased appetite reported in up to
100%, 82%, 90% and 83% of patients with CKD 4 and 5,
respectively [24]. Additionally, fluid and dietary restric-
tions have been recognised to be burdensome and disor-
ienting for patients with CKD with possible strategies to
overcome them including patient-prioritised education
strategies, using the motivation of avoiding dialysis and
viewing adjustment to restrictions as a team effort and
journey for patients, their families and their health profes-
sionals [25]. Our data suggests that addressing these bar-
riers with patients seeing a single specialist rather than a
group of specialists, targeted education of patients about
CKD, and individualised symptom control, emotional sup-
port and psychological screening and treatment may be
very important to patients with co-morbid diabetes and
CKD.
Some patient-reported barriers were associated with a
failure to receive recommended care. Notably, these bar-
riers were different for different items of recommended
care, that is conflicting advice from specialists and inad-
equate support from family and friends being associated
with a HbA1c ≥ 8% (64 mmol/mol); poor communication
between specialists and the effect of co-morbidities on
self-management was associated with not receiving an an-
nual eye check in the presence of diabetic retinopathy;
and feeling unmotivated to self-manage being associated
with a failure to reach a haemoglobin target of 100 –
115 g/L whilst on an ESA. This novel finding implies that
in order to close the gap between recommended and re-
ceived care in co-morbid diabetes and CKD, a “one inter-
vention that fits all” approach is unlikely to be successful
and that specific interventions aiming to improve each
item of recommended care may be required.
Interestingly, the most commonly reported barriers
were not necessarily associated with care gaps. There are
a few possible explanations for this. Firstly, the achieve-
ment of treatment targets and standards of care is an
extremely complex interaction between patients and
their health-care providers. There are possible health-
care provider factors such as a lack of knowledge about
Table 2 Guideline recommended care vs. received care
Recommended care Met Unmet P
HbA1c < 8% (64 mmol/mol) when eGFR
< 60 mL/min/1.73 m2 [7]
68.1% (192/282) 31.9% (90/282) <0.00001
Blood pressure < 140/90 mmHg [7, 8] 60.7% (187/308) 39.3% (121/308) <0.00001
A statin is recommended in patients with
non-dialysis dependent CKD [7]
82.3% (205/249) 17.7% (44/249) <0.00001
In the setting of diabetic retinopathy, eye
examinations should be repeated annually
by an optometrist/ophthalmologist [20]
87.8% (108/123) 12.2% (15/123) <0.00001
In the setting of peripheral neuropathy feet
should be examined every 3 months [20, 37]
49.1% (53/108) 50.9% (55/108) 0.68
Metformin should be ceased if eGFR≤ 30
ml/min/m2 [7]
96.2% (154/160) 3.8% (6/160) <0.00001
ESAa prescribed if Hb < 100 g/L, allowing for
individualisation [19]
50.0% (11/22) 50.0% (11/22) 1.00
Hb between 100 and 115 g/L while on ESA [19] 31.3% (20/64) 68.8% (44/64) <0.00001
aESA = Erythropoietin Stimulating Agent
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treatment targets and standards of care, or treatment in-
ertia [26, 27] which need to be accounted for, and may
not be considered by patients. Secondly, the perceptions
of different barriers and treatment priorities of health
professionals, which are usually delivering recommended
care according to guidelines, and of patients may be
vastly different. This is consistent with a previous study
amongst patients with type 2 diabetes and their health
professionals concluding that patients were less aware
than physicians concerning many of the barriers to good
blood glucose control, high-lighting the need to raise
patients’ awareness [28]. Combined with our findings in
patients with co-morbid diabetes and CKD, this empha-
sises the importance of health care systems addressing
the key barriers identified by health professionals and
also patient-reported barriers known to be associated
with suboptimal treatment targets.
Conflicting advice from specialists is a pitfall associ-
ated with poor continuity of care and in our study
was associated with suboptimal glycaemic control.
The exact mechanism behind the association between
continuity of care and glycaemic control is ill-defined,
although a common denominator in studies of pa-
tients with diabetes alone, seems to be shared health
information which would most likely lead to consist-
ent advice given by the health professional to the pa-
tient [29–32]. This may explain why differing advice
from specialists was associated with the level of
HbA1c. Similarly, inadequate support from family and
friends was also associated with suboptimal glycaemic
control. Although not previously reported in co-
morbid diabetes and CKD, this is consistent with pre-
vious studies amongst patients with diabetes demon-
strating a relationship between family and friend
Fig. 2 Deviation from optimal care according to CKD stage. For all items of recommended care according to guidelines, comparisons between
CKD stages were not statistically significant at the 5% level for Chi square or Fisher exact tests and for linear trends
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support and glycaemic control [33], as well as better
self-care [34, 35] and diabetes management [36].
The strengths of this study are the multi-site recruit-
ment of patients from geographically distinct large metro-
politan areas and exploration of barriers to health-care
identified from previous qualitative work, ensuring that
the work is inductive instead of deductive. The study limi-
tations include the inability to make definitive causal infer-
ences because of the cross-sectional study design as well
as our inability to consider the impact of individualisation
of patient care, especially in the situations where thera-
peutic goals are appropriately different from the treatment
targets. Additionally, we were unable to adequately recruit
all ethnic groups or Aboriginal and/or Torres Strait
Islander people and exclude responder/selection bias.
However, patients (at one tertiary health service) who
participated in the study were similar in age, gender distri-
bution and KDOQI CKD stage to those who did not.
Fig. 3 Significant barriers to health-care identified by patients
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Conclusions
In conclusion, gaps between recommended and received
care exist in the management of co-morbid diabetes and
CKD in tertiary health-care. Barriers to health-care var-
ied across CKD stage and hospitals. However, barriers
related to poor continuity of care were commonly re-
ported by patients and also associated with a failure to
reach good glycaemic control. Other barriers associated
with a deviation from recommended care were different
for different items of recommended care, suggesting that
specific interventions aiming to improve each item of
recommended care are required to improve health-care
for co-morbid diabetes and CKD.
Additional file
Additional file 1: Supplementary Appendix which contains: Part A:
Further information about the Survey Instrument. Part B: Barriers to Health-
care Questionnaire. Table S1. Characteristics of patients who did and did
not participate in the study at one hospital site. Table S2. Characteristics
and medication usage of patients with diabetes and CKD stratified by CKD
stage. Figure S1. Other barriers to health-care identified by patients.
Table S3. Barriers to health-care identified by patients per hospital.
Table S4. The four most common barriers to health-care identified
by patients according to hospital. (DOCX 76 kb)
Abbreviations
CKD: Chronic kidney disease; GP: General practitioner; HbA1c: Glycated
haemoglobin
Acknowledgements
We want to acknowledge S Chaviaras, D Giannopoulos, R McGrath and S
Coggan for help in study conduct.
Funding
This study was supported by a National Health and Medical Research
Council, Australia (NHMRC) Partnership Grant (ID 1055175) between the
following health services, research institutes and national consumer
stakeholder groups – Alfred Health; Concord Hospital; Royal North Shore
Hospital; Monash Health; Monash Centre for Health Research and
Implementation, Monash University; The George Institute for Global Health,
University of Sydney; Diabetes Australia; and Kidney Health Australia. The
NHMRC had no role in the design, data collection, data analysis or
interpretation of data for this study.
C Lo was supported by an Australian Postgraduate Award Scholarship. H
Teede was supported by a NHMRC, Australia Fellowship. S Zoungas was
supported by a National Heart Foundation of Australia Fellowship.
Availability of supporting data
Datasets used and/or analysed from this study are available on reasonable
request by contacting Clement Lo at clement.lo@monash.edu.
Authors’ contributions
CL, HT, and SZ contributed to the original conception and design of the
work, collection, analysis and interpretation of the data, and the drafting of
this manuscript. GF, MG, PK, SR, GR and RW contributed to the collection,
analysis and interpretation of the data, and critical revision of the manuscript
for intellectual content. All authors approved the final version to be
published.
Competing interests




Ethics approval and consent to participate
This study was approved by all local hospital and university Human Research
Ethics Committees (Monash Health Human Research Ethics Committee,
Alfred Health Research Ethics Committee, Monash University Human
Research Ethics Committee, Northern Sydney Local Health District Human
Research Ethics Committee, Sydney Local Health District Human Research
Ethics Committee and the University of Sydney Human Research Ethics
Committee). All participants were involved voluntarily and gave written
consent for participation in and audio-recording of focus groups or semi-
structured interviews.
Author details
1Diabetes and Vascular Research Program, Monash Centre for Health
Research and Implementation, School of Public Health and Preventive
Medicine, Monash University, Clayton, Victoria, Australia. 2Diabetes and
Vascular Medicine Unit, Monash Health, Clayton, Victoria, Australia. 3Department
of Diabetes and Endocrinology, Royal North Shore Hospital, St Leonards, New
South Wales, Australia. 4Department of Nephrology, Concord Hospital, Concord,
New South Wales, Australia. 5The George Institute for Global Health, Sydney, New
South Wales, Australia. 6Department of Nephrology, Monash Health, Clayton,
Victoria, Australia. 7School of Primary Health Care, Monash University, Notting Hill,
Victoria, Australia. 8Department of Renal Medicine, Alfred Health, Prahran, Victoria,
Australia.
Received: 16 November 2016 Accepted: 21 February 2017
References
1. IDF. IDF Diabetes Atlas 6th Edition. 2013.
2. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al.
Excerpts from the United States Renal Data System 2006 Annual Data
Report. Am J Kidney Dis. 2007;49(1 Suppl 1):A6–7. doi:10.1053/j.ajkd.2006.11.
019. S1-296.
3. Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity’s
many challenges. BMJ. 2007;334(7602):1016–7. doi:10.1136/bmj.39201.
463819.2C.
4. Atun R. Transitioning health systems for multimorbidity. Lancet. 2015. doi:
10.1016/s0140-6736(14)62254-6.
5. Radbill BMB, LeRoith D. Rationale and strategies for early detection and
management of diabetic kidney disease. Mayo Clin Proc. 2008;83(12):1373–81.
6. Ozieh MN, Dismuke CE, Lynch CP, Egede LE. Medical care expenditures
associated with chronic kidney disease in adults with diabetes: United
States 2011. Diabetes Res Clin Pract. 2015. doi:10.1016/j.diabres.2015.04.011.
7. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et
al. Diabetic kidney disease: a report from an ADA Consensus Conference.
Diabetes Care. 2014;37(10):2864–83. doi:10.2337/dc14-1296.
8. Clinical Practice Guideline on management of patients with diabetes and
chronic kidney disease stage 3b or higher (eGFR <45 mL/min). Nephrol Dial
Transplant. 2015;30(Suppl 2):ii1-ii142. doi:10.1093/ndt/gfv100.
9. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J
Kidney Dis. 2012;60(5):850–86. doi:10.1053/j.ajkd.2012.07.005.
10. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, et al. The CARI
guidelines. Prevention and management of chronic kidney disease in type 2
diabetes. Nephrology (Carlton). 2010;15 Suppl 1:S162–94. 10.1111/j.1440-
1797.2010.01240.x.
11. Hill CJ, Cardwell CR, Patterson CC, Maxwell AP, Magee GM, Young RJ, et al.
Chronic kidney disease and diabetes in the national health service: a cross-
sectional survey of the U.K. national diabetes audit. Diabet Med. 2014;31(4):
448–54. doi:10.1111/dme.12312.
12. De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S et al.
Achievement of therapeutic targets in patients with diabetes and chronic
kidney disease: insights from the Associazione Medici Diabetologi Annals
initiative. Nephrol Dial Transplant. 2015. doi:10.1093/ndt/gfv101.
13. Stevens PE, Schernthaner G, Raptis S, Wanner C, Scherhag A, Lameire N.
Characteristics, cardiovascular comorbidity and medicines management in
patients with type 2 diabetes and CKD: results of the IRIDIEM study. Kidney
Blood Press Res. 2010;33(2):119–28. doi:10.1159/000313595.
Lo et al. BMC Nephrology  (2017) 18:80 Page 9 of 10
14. 2014 US Renal Data System Annual Data Report Ann Arbor, Michigan,
USRDS Coordinating Center 2014.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Lancet. 2007;370(9596):1453–7. doi:10.1016/s0140-6736(07)61602-x.
16. WHO. Definition and diagnosis of diabetes mellitus and intermediate
hyperglycemia. Geneva: World Health Organisation; 2006.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et
al. A new equation to estimate glomerular filtration rate. Ann Intern Med.
2009;150(9):604–12.
18. Lo C, Ilic D, Teede H, Cass A, Fulcher G, Gallagher M et al. The Perspectives
of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney
Disease: A Qualitative Study. 2016(1932–6203 (Electronic)). doi:D - NLM:
PMC4701448 EDAT- 2016/01/06 06:00 MHDA- 2016/01/06 06:00 CRDT-
2016/01/06 06:00 PHST- 2016 [ecollection] PHST- 2015/09/17 [received]
PHST- 2015/12/18 [accepted] PHST- 2016/01/05 [epublish] AID - 10.1371/
journal.pone.0146615 [doi] AID - PONE-D-15-40881 [pii] PST - epublish.
19. KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney
disease. Kideny Int. 2012;2(2):279–335.
20. ADA. Standards of medical care in diabetes - 2015. Diabetes Care. 2015;
38(1):S1–S93.
21. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. American journal of kidney diseases: the
official journal of the National Kidney Foundation. 2002;39(2 Suppl 1):S1-266.
22. Plantinga LC, Boulware LE, Coresh J, Stevens LA, Miller 3rd ER, Saran R, et al.
Patient awareness of chronic kidney disease: trends and predictors. Arch
Intern Med. 2008;168(20):2268–75. doi:10.1001/archinte.168.20.2268.
23. Wright JA, Wallston KA, Elasy TA, Ikizler TA, Cavanaugh KL. Development
and results of a kidney disease knowledge survey given to patients with
CKD. Am J Kidney Dis. 2011;57(3):387–95. doi:10.1053/j.ajkd.2010.09.018.
24. Almutary H, Bonner A, Douglas C. Symptom burden in chronic kidney
disease: a review of recent literature. J Ren Care. 2013;39(3):140–50. doi:10.
1111/j.1755-6686.2013.12022.x.
25. Palmer SC, Hanson CS, Craig JC, Strippoli GF, Ruospo M, Campbell K, et al.
Dietary and fluid restrictions in CKD: a thematic synthesis of patient views
from qualitative studies. Am J Kidney Dis. 2015;65(4):559–73. doi:10.1053/j.
ajkd.2014.09.012.
26. Puder JJ, Keller U. Quality of diabetes care: problem of patient or doctor
adherence? (1424–7860 (Print)).
27. Hasan H, Zodpey S Fau - Saraf A, Saraf A. Diabetologist’s perspective on
practice of evidence based diabetes management in India. (1872–8227
(Electronic)).
28. Suzuki T, Takei R, Inoguchi T, Sonoda N, Sasaki S, Kaise T et al. Clinical
significance of barriers to blood glucose control in type 2 diabetes patients
with insufficient glycemic control. (1177-889X (Electronic)). doi:D - NLM:
PMC4485849 OTO - NOTNLM.
29. Litaker D, Ritter C Fau - Ober S, Ober S Fau - Aron D, Aron D. Continuity of
care and cardiovascular risk factor management: does care by a single
clinician add to informational continuity provided by electronic medical
records? (1088–0224 (Print)).
30. Mainous AG, 3rd, Koopman Rj Fau - Gill JM, Gill Jm Fau - Baker R, Baker R
Fau - Pearson WS, Pearson WS. Relationship between continuity of care and
diabetes control: evidence from the Third National Health and Nutrition
Examination Survey. (0090–0036 (Print)). doi:D - NLM: PMC1449828 EDAT-
2004/01/10 05:00 MHDA- 2004/02/13 05:00 CRDT- 2004/01/10 05:00 PST -
ppublish.
31. O’Connor PJ, Desai J Fau - Rush WA, Rush Wa Fau - Cherney LM, Cherney
Lm Fau - Solberg LI, Solberg Li Fau - Bishop DB, Bishop DB. Is having a
regular provider of diabetes care related to intensity of care and glycemic
control? (0094–3509 (Print)).
32. Dearinger AT, Wilson Jf Fau - Griffith CH, Griffith Ch Fau - Scutchfield FD,
Scutchfield FD. The effect of physician continuity on diabetic outcomes in a
resident continuity clinic. (1525–1497 (Electronic)). doi:D - NLM:
PMC2517915 EDAT- 2008/07/10 09:00 MHDA- 2008/08/30 09:00 CRDT-
2008/07/10 09:00 AID - 10.1007/s11606-008-0654-5 [doi] PST - ppublish.
33. Shawon MS, Hossain FB, Adhikary G, Das Gupta R, Hashan MR, Rabbi MF et
al. Attitude towards diabetes and social and family support among type 2
diabetes patients attending a tertiary-care hospital in Bangladesh: a cross-
sectional study. (1756–0500 (Electronic)). doi:D - NLM: PMC4881197 OTO -
NOTNLM.
34. Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of
blood glucose in people with type 2 diabetes using insulin: a qualitative
study. (1177-889X (Electronic)). doi:D - NLM: PMC3931581 OTO - NOTNLM.
35. Laranjo L, Neves Al Fau - Costa A, Costa A Fau - Ribeiro RT, Ribeiro Rt Fau -
Couto L, Couto L Fau - Sa AB, Sa AB. Facilitators, barriers and expectations
in the self-management of type 2 diabetes–a qualitative study from
Portugal. (1751–1402 (Electronic)).
36. Singh H, Cinnirella M Fau - Bradley C, Bradley C. Support systems for and
barriers to diabetes management in South Asians and Whites in the UK:
qualitative study of patients’ perspectives. LID - 10.1136/bmjopen-2012-
001459 [doi] LID - e001459 [pii]. (2044–6055 (Electronic)). doi:D - NLM:
PMC3532968 EDAT- 2012/11/16 06:00 MHDA- 2012/11/16 06:01 CRDT-
2012/11/16 06:00 PHST- 2012 [ppublish] AID - bmjopen-2012-001459 [pii]
AID - 10.1136/bmjopen-2012-001459 [doi] PST - epublish.
37. National Evidence-Based Guidelines on Prevention, Identification and
Management of Foot Complications in Diabetes (Part of the Guidelines on
the Management of Type 2 Diabetes). Melbourne, Australia2011.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lo et al. BMC Nephrology  (2017) 18:80 Page 10 of 10
